On December 3, 2025, EPN submitted formal comments urging EPA to delay registering epyrifenacil, citing incomplete cumulative risk assessments, insufficient ecological and human health analysis, and labeling shortcomings that could endanger listed species, impair compliance, and fail to adequately protect public health and the environment.
EPN Comments on Memorandum Supporting Proposed Decision to Approve Registration for the New Active Ingredient, Epyrifenacil
